Roche’s Ocrevus Shines in Relapsing-Remitting MS, Safety Studies

Genentech (Roche)’s Ocrevus (ocrelizumab) stole the show at last month’s European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting, particularly in relapsing-remitting MS (RRMS).